US 11344552

An analysis of US Patent 11,344,552 reveals a targeted therapy for pancreatic cancer, currently facing legal challenges.

Patent Details:

• Title: Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin.
• Assignee: Ipsen Biopharm Ltd.
• Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, and Helen Lee.
• Filing Date: November 10, 2017.
• Issue Date: May 31, 2022.
• Abstract: The patent describes combination therapy regimens for treating pancreatic cancer, specifically for patients with previously untreated metastatic adenocarcinoma of the pancreas. The treatment involves administering liposomal irinotecan, oxaliplatin, and 5-fluorouracil, with the option of also including leucovorin, on a bi-weekly schedule.

Independent Claims:

The patent includes two independent claims that outline a specific method for treating a particular type of pancreatic cancer.

• Claim 1: This claim details a method for treating metastatic adenocarcinoma of the pancreas in patients who have not previously received antineoplastic agents for this condition. The method involves administering a specific combination of drugs every two weeks: 60 mg/m² of liposomal irinotecan, 60 mg/m² of oxaliplatin, 200 mg/m² of the (l)-form of leucovorin or 400 mg/m² of the racemic form of leucovorin, and 2,400 mg/m² of 5-fluorouracil.
• Claim 12: This claim is similar to claim 1, but it specifies that the patient has not previously received gemcitabine for the treatment of metastatic adenocarcinoma of the pancreas. The treatment regimen is identical to that described in claim 1.

Litigation:

As of the current date, US Patent 11,344,552 is the subject of two pending Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. These IPRs, initiated by CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., and Conjupro Biotherapeutics, Inc. (IPR2025-00505) and another by "Unified Patents" (IPR2025-01531), challenge the validity of the patent's claims, asserting that the claimed invention would have been obvious in light of prior art. The petitioners argue that the combination of liposomal irinotecan with existing chemotherapy regimens like FOLFIRINOX was a predictable development.

There is no information publicly available regarding any appeals of these IPR decisions to the Court of Appeals for the Federal Circuit (CAFC) at this time.

Here's a summary of the known litigation involving US Patent 11,344,552:

1. Inter Partes Review (IPR2025-00505)

• Plaintiff(s): CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjupro Biotherapeutics, Inc.
• Defendant(s): Ipsen Biopharm Ltd.
• Jurisdiction: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.
• Case Number: IPR2025-00505
• Filing Date: January 16, 2025 (or January 17, 2025)
• Current Status: Pending - Instituted. The PTAB decided to institute the IPR on August 14, 2025. Ipsen Biopharm Ltd. filed a request for discretionary denial, but the Acting Director of the USPTO declined to exercise discretionary denial, finding the petitioners' arguments persuasive regarding potential material error during the original patent prosecution.

2. Inter Partes Review (IPR2025-01531)

• Plaintiff(s): Unified Patents
• Defendant(s): Ipsen Biopharm Ltd.
• Jurisdiction: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.
• Case Number: IPR2025-01531
• Filing Date: No specific filing date is provided in the search results, but it is indicated as "filed" and "Instituted".
• Current Status: Pending - Instituted.

3. District Court Litigation (Consolidated Cases)

• Plaintiff(s): IPSEN BIOPHARMACEUTICALS, INC. and IPSEN BIOPHARM LTD.
• Defendant(s): CONJUPRO BIOTHERAPEUTICS, INC., CSPC PHARMACEUTICAL GROUP LIMITED and CSPC OUYI PHARMACEUTICAL CO., LTD.
• Jurisdiction: U.S. District Court for the District of New Jersey
• Case Numbers: 1:2024cv04991 (filed April 15, 2024) and 1:2025cv13647 (filed July 22, 2025). These cases were consolidated under case number 1:2025cv13647.
• Filing Dates: April 15, 2024 (for 1:2024cv04991) and July 22, 2025 (for 1:2025cv13647)
• Current Status: The case is a civil action for patent infringement, specifically an Abbreviated New Drug Application (ANDA) related case. As of September 5, 2025, the cases were consolidated, and the clerk was directed to administratively terminate case 1:2025cv13647. The docket was last retrieved on September 9, 2025.

Proceedings overview

Based on the canonical list of PTAB proceedings provided, there is one active Inter Partes Review (IPR) challenging US Patent 11,344,552. This IPR, IPR2025-01531, is currently in the "Trial Instituted" status, meaning the Patent Trial and Appeal Board has found a reasonable likelihood that at least one challenged claim is unpatentable and has authorized a trial. The outcome of this proceeding is still pending, so the patent's defensive posture for a defendant remains uncertain until a Final Written Decision is issued.

It is important to note a contradiction between the "Previously generated sections" and the "PTAB proceedings on file" provided. The "Patent summary" section mentions two IPRs: IPR2025-00505 by CSPC Pharmaceutical Group Ltd. et al., and IPR2025-01531 by "Unified Patents". However, the "PTAB proceedings on file" section, which is to be treated as the canonical list, only lists IPR2025-01531, with "Apotex Inc." as the petitioner. As per instructions, this analysis will proceed based only on the canonical list provided in "PTAB proceedings on file".

IPR2025-01531 — Apotex Inc. v. Ipsen Biopharm Ltd

• Type: Inter Partes Review
• Filed: 2025-09-12
• Status: Trial Instituted. The PTAB has decided to institute a trial on the challenged claims.
• Judge panel: Information regarding the specific judge panel for this instituted IPR is not publicly available at this stage in the provided patent text or through a quick general search.
• Petition grounds: The petition by Apotex Inc. for IPR2025-01531 challenges claims 1-19 of U.S. Patent No. 11,344,552 as unpatentable under 35 U.S.C. § 103 over a combination of prior art references including US 2014/0343006 to Von Hoff, WO 2011/140327 to Merrimack Pharmaceuticals, and WO 2013/112937 to Merrimack Pharmaceuticals.
• Institution decision: The PTAB instituted review of claims 1-19 on 2026-03-12. The Board found that Apotex Inc. demonstrated a reasonable likelihood that the challenged claims are unpatentable in view of the cited prior art.
• Final Written Decision: Not yet issued. The statutory one-year deadline for a Final Written Decision from institution is 2027-03-12.
• Settlement / termination: No information available regarding settlement or termination.
• Appeal: Not applicable, as a Final Written Decision has not yet been issued.
• Defensive value: This IPR poses a significant challenge to all claims (1-19) of the patent. If the IPR results in the cancellation of these claims, it would severely weaken any assertion of this patent. Conversely, if claims are sustained, it would strengthen the patent against future obviousness challenges based on the same prior art.

Strategic summary

Currently, all claims (1-19) of US Patent 11,344,552 are under review in IPR2025-01531. As the trial has been instituted, no claims have yet been canceled or sustained through a Final Written Decision from this proceeding. Therefore, all claims remain untested in terms of a final PTAB validity determination based on the merits of the arguments presented in this IPR.

Regarding the estoppel landscape, if IPR2025-01531 proceeds to a Final Written Decision, Apotex Inc. (and any parties in privity with them) would be estopped under 35 U.S.C. § 315(e)(2) from asserting in future District Court litigation or other USPTO proceedings that claims 1-19 are invalid on any ground that Apotex Inc. raised or reasonably could have raised in this IPR. For other potential defendants, the specific prior art references (US 2014/0343006 to Von Hoff, WO 2011/140327, and WO 2013/112937 to Merrimack Pharmaceuticals) used in the petition's obviousness grounds may be limited if they are in privity with Apotex or if the claims are affirmed. However, if claims are cancelled, the patent owner would be estopped from asserting those claims.

There is a pattern signal in that Apotex Inc. is the petitioner, suggesting a potential challenge from a generic drug manufacturer. The mention of "Unified Patents" as a petitioner in the "Patent summary" for IPR2025-01531, though contradicted by the canonical "PTAB proceedings on file" list which names "Apotex Inc." as the petitioner, would have indicated the involvement of a defensive aggregator had it been accurate.

Recommended next steps

• Since IPR2025-01531 is active and has been instituted, closely monitor its progress. The Final Written Decision is due by 2027-03-12.
• Review the institution decision for IPR2025-01531 to understand the specific reasoning for institution and the Board's preliminary assessment of the challenged claims. This will provide insight into the strength of the petitioner's arguments and the potential weaknesses of the patent claims. The institution decision is available on the PTAB E2E system.
• Analyze the prior art presented by Apotex Inc. in IPR2025-01531 (US 2014/0343006 to Von Hoff, WO 2011/140327, and WO 2013/112937 to Merrimack Pharmaceuticals) to understand the nature of the obviousness challenge. This is crucial for assessing potential future validity arguments, regardless of the IPR's outcome.
• If facing assertion of this patent, consider whether any claims currently under review are being asserted. The outcome of the IPR will directly impact the viability of such assertions.

Inventors

• Eliel Bayever (Merrimack Pharmaceuticals, Inc.)
• Sarah F. Blanchette (Merrimack Pharmaceuticals, Inc.)
• Jonathan Basil Fitzgerald (Merrimack Pharmaceuticals, Inc.)
• Daniel F. Gaddy (Merrimack Pharmaceuticals, Inc.)
• Bart S. Hendriks (Merrimack Pharmaceuticals, Inc.)
• Ashish Kalra (Merrimack Pharmaceuticals, Inc.)
• Helen Lee (Merrimack Pharmaceuticals, Inc.)

At the time of filing (November 10, 2017), the inventors had assigned their rights to Merrimack Pharmaceuticals, Inc., which then assigned to Ipsen Biopharm Ltd. The application was filed by Ipsen Biopharm Ltd. All inventors were associated with Merrimack Pharmaceuticals, Inc. when the initial assignments were executed.

Original assignee

Ipsen Biopharm Ltd. is listed as the original assignee on the issued patent and the entity that filed the application. Ipsen Biopharm Ltd. is a global pharmaceutical company. They market ONIVYDE® (liposomal irinotecan), a product embodying aspects related to the claims for the treatment of metastatic pancreatic adenocarcinoma. The company is currently operating.

Assignment timeline

• 2017-02-07 (executed) / recorded 2018-02-07 — Reel 045172/0322

  • Conveyance: Assignment
  • Assignor: Kalra, Ashish; Blanchette, Sarah F.; Fitzgerald, Jonathan Basil; Lee, Helen; Bayever, Eliel; Hendriks, Bart S.; Gaddy, Daniel F.
  • Assignee: Merrimack Pharmaceuticals, Inc.
  • Correspondent: Elizabeth F. Allison, CHOATE HALL & STEWART LLP, 2 SEAPORT LANE, BOSTON, MA 02210.
  • Context: Transfer of inventor rights to an operating company.

• 2017-02-07 (executed) / recorded 2018-02-07 — Reel 045172/0333

  • Conveyance: Assignment
  • Assignor: Merrimack Pharmaceuticals, Inc.
  • Assignee: Ipsen Biopharm Ltd.
  • Correspondent: Elizabeth F. Allison, CHOATE HALL & STEWART LLP, 2 SEAPORT LANE, BOSTON, MA 02210. This correspondent also appears on the preceding assignment in this chain.
  • Context: Acquisition of oncology assets by Ipsen, including the rights to this invention.

Timeline diagram

timeline
    title Ownership of US 11344552
    2017 : Inventors assigned to Merrimack
         : Merrimack assigned to Ipsen
    2022 : Patent issued to Ipsen
    2024 : First infringement suit filed
    2025 : IPRs instituted against Ipsen

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The assignor Merrimack Pharmaceuticals, Inc. and the assignee Ipsen Biopharm Ltd. are both operating pharmaceutical companies.
2. Known asserter in the chain — not present. Neither Merrimack Pharmaceuticals, Inc. nor Ipsen Biopharm Ltd. are identified as known patent asserters (NPEs).
3. Repeat correspondent across the chain — present. Elizabeth F. Allison of Choate Hall & Stewart LLP is listed as the correspondent for both assignments (Reel 045172/0322 and Reel 045172/0333). These assignments represent a single transaction where intellectual property rights were transferred from the inventors to Merrimack, and then from Merrimack to Ipsen.
4. Cascading transfers — not present. There are only two assignments, both related to the same asset acquisition and recorded on the same date.
5. Pre-litigation transfer — not present. The assignments were recorded in 2018. The first identified district court litigation was filed in April 2024, significantly more than six months after the assignments.
6. Bankruptcy fire-sale — not present. Merrimack Pharmaceuticals, Inc. sold its oncology assets, including ONIVYDE, to Ipsen in 2017 as a strategic asset sale, not due to bankruptcy.
7. Privateering — not present. Ipsen Biopharm Ltd. is an operating pharmaceutical company asserting its own intellectual property.
8. Defensive aggregator (anti-NPE) — not present. The patent is currently held by an operating pharmaceutical company.

Verdict

Operating-company assertion

Ipsen Biopharm Ltd. is an operating pharmaceutical company that markets ONIVYDE®, a product related to the claims of this patent. The assignments recorded (Reel 045172/0322 and Reel 045172/0333) reflect a transfer of assets between two operating companies, ultimately leading to Ipsen holding the patent rights. The ongoing litigation involves Ipsen asserting its patent rights in district court against competitors, which is characteristic of an operating-company assertion.

USPTO Patent Assignment Search for US11344552

To identify the most relevant prior art for US patent 11344552, I will examine the patent's citations. A prior art reference "anticipates" a claim under 35 U.S.C. § 102 if every element of the claimed invention is identically disclosed in a single prior art reference.

Here are some of the most relevant patent citations for US11344552B2, along with their details:

US 10993914 B2: Stabilizing camptothecin pharmaceutical compositions

• Full Citation: US 10993914 B2, "Stabilizing camptothecin pharmaceutical compositions," granted May 11, 2021.
• Publication/Filing Date: Claims priority to provisional applications filed October 16, 2015.
• Brief Description: This patent describes injectable liposome pharmaceutical products for treating cancer, specifically encapsulating camptothecin compounds (like irinotecan or topotecan) with a polyanionic trapping agent within liposomes. It also mentions that liposomal irinotecan compositions can be administered in combination with other antineoplastic agents, such as 5-fluorouracil and leucovorin for metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, or with 5-fluorouracil, leucovorin, and oxaliplatin for previously untreated pancreatic cancer.
• Potential Anticipation (35 U.S.C. § 102): This patent broadly describes a combination therapy including liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin for previously untreated pancreatic cancer. This description could potentially anticipate aspects of claims 1 and 12 of US 11344552B2, particularly the general concept of the drug combination for previously untreated pancreatic cancer, as both claims involve liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin for previously untreated metastatic adenocarcinoma of the pancreas. The specific dosages and administration schedules of US11344552B2 would need to be critically compared against the disclosure of US 10993914 B2 to determine if "every element" is identically shown.

US 12364691 B2: Methods for treating pancreatic cancer using combination therapies

• Full Citation: US 12364691 B2, "Methods for treating pancreatic cancer using combination therapies," granted December 26, 2023.
• Publication/Filing Date: Priority date June 13, 2012.
• Brief Description: This patent provides methods for treating pancreatic cancer by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. One embodiment specifies co-administration of liposomal irinotecan (MM-398) with 5-fluorouracil and leucovorin. It also mentions the therapy can be safely administered to patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, with specific doses of leucovorin.
• Potential Anticipation (35 U.S.C. § 102): While this patent describes combination therapy with liposomal irinotecan, 5-FU, and leucovorin, it does not explicitly include oxaliplatin in the primary described combination for pancreatic cancer. However, if any claims in US11344552B2 are broad enough to cover combinations without oxaliplatin (which the independent claims 1 and 12 of US11344552B2 do not, as they explicitly include oxaliplatin), or if the inclusion of oxaliplatin could be considered an obvious addition given the context of other treatments, it could be relevant. Claims 1 and 12 of US11344552B2 specifically include oxaliplatin, so this patent would not directly anticipate these claims under a strict interpretation of 35 U.S.C. § 102 (requiring every element). However, it could be highly relevant for an obviousness argument under 35 U.S.C. § 103, especially if combined with other prior art teaching the use of oxaliplatin in pancreatic cancer regimens.

Obviousness Analysis of US Patent 11,344,552 under 35 U.S.C. § 103

This analysis evaluates the obviousness of US Patent 11,344,552, focusing on the combination therapies for metastatic pancreatic cancer, in light of the prior art discussed within the patent itself. The core of the invention lies in substituting conventional irinotecan with liposomal irinotecan (MM-398) in a FOLFIRINOX-like regimen.

Elements of Independent Claims 1 and 12

Independent Claim 1 defines a method for treating previously untreated metastatic adenocarcinoma of the pancreas. The method involves administering an antineoplastic therapy every two weeks, consisting of:

• 60 mg/m² liposomal irinotecan (irinotecan sucrose octasulfate encapsulated in liposomes).
• 60 mg/m² oxaliplatin.
• 200 mg/m² (l)-leucovorin or 400 mg/m² (l+d) racemic leucovorin.
• 2,400 mg/m² 5-fluorouracil.

Independent Claim 12 adds the specific limitation that "the patient has not previously received gemcitabine for the treatment of metastatic adenocarcinoma of the pancreas."

Prior Art Combination for Obviousness

A strong argument for obviousness can be constructed by combining the established FOLFIRINOX regimen with the known characteristics and approved use of liposomal irinotecan (MM-398, ONIVYDE®).

Primary Prior Art References:

1. FOLFIRINOX Regimen: The patent explicitly identifies FOLFIRINOX as a standard of care for first-line metastatic pancreatic cancer since 2011, as recommended by the National Comprehensive Cancer Network (NCCN). A typical FOLFIRINOX regimen includes "85 mg/m² oxaliplatin, 180 mg/m² irinotecan, and fluorouracil at a dose of 400 mg/m² administered by IV bolus followed by a continuous infusion of 2400 mg/m²." The patent also notes "concerns about the toxicity associated with FOLFIRINOX."
2. Liposomal Irinotecan (MM-398/ONIVYDE®): The patent describes MM-398 as a liposomal irinotecan that is FDA-approved (marketed as ONIVYDE®) in combination with 5-fluorouracil and leucovorin for treating metastatic adenocarcinoma of the pancreas, specifically "after disease progression following gemcitabine-based therapy." The patent also details the composition of MM-398, stating it "comprises irinotecan sucrose octasulfate encapsulated in liposomes." Furthermore, the patent highlights that "liposomal irinotecan improved anti-tumor activity... relative to exposure-matched doses of non-liposomal irinotecan" and results in "prolonged tumor exposure to the active metabolite, SN-38, compared to non-liposomal irinotecan (CPT-11)."

Motivation to Combine FOLFIRINOX with Liposomal Irinotecan

A person having ordinary skill in the art (POSITA) in the field of oncology or pharmaceutical development, at the time of the invention, would have possessed a clear motivation to combine the FOLFIRINOX regimen with liposomal irinotecan (MM-398). This motivation stems directly from the known limitations of FOLFIRINOX and the recognized advantages of liposomal drug delivery:

1. Addressing FOLFIRINOX Toxicity: The patent acknowledges that "FOLFIRINOX is known to have significant toxicity," leading to concerns and often the use of modified regimens, or discontinuation of oxaliplatin due to toxicity. This established problem with a leading treatment regimen would strongly motivate a POSITA to seek alternatives that maintain or improve efficacy while reducing toxicity.
2. Known Benefits of Liposomal Formulations: The art understood that liposomal encapsulation could improve the therapeutic index of drugs by altering pharmacokinetics, prolonging drug exposure, and potentially reducing systemic toxicity. The patent itself confirms these benefits for MM-398, stating it "improved anti-tumor activity... relative to exposure-matched doses of non-liposomal irinotecan" and that "liposomal irinotecan combined with 5-fluorouracil and oxaliplatin consistently improved tumor growth inhibition and survival in mouse xenograft models of pancreatic cancer relative to non-liposomal irinotecan, without exacerbating the baseline toxicities of these agents."
3. Prior Approval and Use of MM-398 in Pancreatic Cancer: MM-398 was already FDA-approved for metastatic pancreatic cancer, albeit in a second-line setting. This established its safety and efficacy in the target disease and provided direct evidence of its utility in combination with 5-FU and leucovorin. A POSITA would logically consider moving an effective agent to an earlier line of therapy if it offered advantages, such as an improved toxicity profile, especially given the poor prognosis of metastatic pancreatic cancer.

Therefore, the motivation would be to substitute conventional irinotecan in the FOLFIRINOX regimen with liposomal irinotecan (MM-398) with a reasonable expectation of achieving "improved therapeutic index (e.g., improved toxicity profiles) relative to prior FOLFIRINOX regimens."

Reasonable Expectation of Success

The patent's own preclinical data, described in the background and examples, would have provided a POSITA with a reasonable expectation of success for this substitution. For instance, the patent details that "liposomal irinotecan combined with 5-fluorouracil and oxaliplatin consistently improved tumor growth inhibition and survival in mouse xenograft models of pancreatic cancer relative to non-liposomal irinotecan, without exacerbating the baseline toxicities of these agents." This preclinical evidence would further reinforce the expectation that replacing irinotecan in FOLFIRINOX with MM-398 would yield a beneficial outcome.

Routine Optimization and Dose Adjustments

The specific dosage of 60 mg/m² for liposomal irinotecan, 60 mg/m² for oxaliplatin, and the particular administration schedule are likely considered routine optimization within the skill of the art. The patent itself notes that an initial dose of "80 mg/m² liposomal irinotecan was not well tolerated in humans when administered in combination with 60 mg/m² oxaliplatin, 2400 mg/m² 5-fluorouracil and 400 mg/m² (l+d) leucovorin." Consequently, the claimed "preferred methods... provide for the administration of a human-tolerated antineoplastic therapy once every two weeks" with a reduced dose of 60 mg/m² liposomal irinotecan. This process of dose-finding and adjustment to achieve an optimal balance of efficacy and tolerability is a common practice in clinical oncology and falls within the purview of routine experimentation, not inventive ingenuity.

Conclusion on Obviousness

The combination therapy claimed in US Patent 11,344,552, as outlined in independent claims 1 and 12, would likely be considered obvious to a POSITA. The FOLFIRINOX regimen provided all the components of the claimed therapy (irinotecan, oxaliplatin, 5-FU, leucovorin) for the same indication (metastatic pancreatic cancer). The liposomal irinotecan (MM-398) was a known drug with established benefits of improved therapeutic index due to its liposomal formulation, and it was already approved for pancreatic cancer. The known toxicity of FOLFIRINOX would have provided a clear motivation to substitute the conventional irinotecan with liposomal irinotecan, with a reasonable expectation of success supported by the general understanding of liposomal drug delivery and the specific preclinical data for MM-398. The dose adjustments represent routine optimization. The additional limitation in Claim 12 regarding prior gemcitabine treatment is a patient selection criterion, not a novel aspect of the drug combination itself, and would be a logical extension of MM-398's established use.

To provide a comprehensive analysis of US Patent 11,344,552 regarding patent term adjustments (PTA), patent term extensions (PTE), continuation/divisional applications, related family members, and projected expiration date, direct access to the USPTO's Patent Center or PAIR (Patent Application Information Retrieval) system is typically required. Public Google searches provide some information, but a direct USPTO database search would yield the most precise and complete details.

Based on the available information:

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is additional time added to the term of a U.S. patent to compensate for delays caused by the USPTO during the prosecution of a utility or plant patent application. This adjustment is typically calculated after the patent is granted. Factors such as delays in issuing office actions, responding to applicant replies, or issuing the patent can contribute to PTA.

The provided information does not explicitly state the specific PTA granted for US Patent 11,344,552. To determine the exact PTA, one would need to access the official patent file in the USPTO's Patent Center or PAIR system.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is a statutory remedy, primarily under 35 U.S.C. § 156, designed to restore patent term lost due to the lengthy regulatory review process for certain products, particularly pharmaceuticals and medical devices, by agencies like the FDA.

The patent text for US 11,344,552 mentions that MM-398 (liposomal irinotecan, marketed as ONIVYDE®) is an FDA-approved product. Given that the patent covers methods for treating metastatic pancreatic cancer using this drug combination, it is a candidate for PTE. However, the available information does not specify if a PTE was applied for or granted for US Patent 11,344,552. An application for PTE must be submitted to the USPTO within 60 days of regulatory agency approval of the commercial marketing application. Only one patent can be extended for a regulatory review period for any product, and the extension is limited to a maximum of five years, and the total post-approval patent life cannot exceed 14 years from the date of FDA approval.

Continuation and Divisional Applications

• Continuation Applications: US Patent 11,344,552 is explicitly stated to be a "continuation of U.S. application Ser. No. 15/241,106, filed Aug. 19, 2016".
• Divisional Applications: The provided information does not explicitly mention any divisional applications directly stemming from US Patent 11,344,552 or its direct parent.

Related Family Members

The patent states it claims the benefit of priority to several U.S. Provisional Application Nos.:

• 62/208,209, filed Aug. 21, 2015
• 62/216,736, filed Sep. 10, 2015
• 62/273,244, filed Dec. 30, 2015
• 62/281,473, filed Jan. 21, 2016
• 62/302,341, filed Mar. 2, 2016
• 62/323,245, filed Apr. 15, 2016
• 62/343,313, filed May 31, 2016

It is also a continuation of U.S. Application Ser. No. 15/241,106, filed August 19, 2016.

Additionally, the "Other versions" section of the Google Patents page lists US20180078556A1, which is a published application related to this patent. Other priority claims are mentioned, including US17/711,500 (priority to 2022-04-01), US18/676,591 (priority to 2024-05-29), and US19/188,672 (priority to 2025-04-24). These suggest further related applications, possibly continuations or divisionals, that have been filed more recently.

Projected Expiration Date

The general rule for utility patents is that the term ends 20 years from the filing date of the earliest non-provisional application for which a benefit is claimed under 35 U.S.C. § 120, 121, or 365(c). This patent claims priority from a U.S. non-provisional application filed on August 19, 2016 (U.S. application Ser. No. 15/241,106), which itself claims priority to several provisional applications, with the earliest priority date being August 21, 2015.

Therefore, the unadjusted statutory expiration date would be 20 years from the earliest non-provisional filing date (August 19, 2016), which would be August 19, 2036.

This date would then be adjusted by any Patent Term Adjustments (PTA) for USPTO delays and potentially extended by any Patent Term Extensions (PTE) due to regulatory review delays. As noted above, the specific PTA or PTE amounts are not publicly available in the provided text. The anticipated expiration date listed on Google Patents is also 2036-08-19.

Defensive Disclosure: Derivative Variations of US Patent 11,344,552

This document outlines derivative variations of the core claims of US Patent 11,344,552, aimed at creating defensive prior art. The focus is on the combination therapy for metastatic pancreatic cancer, particularly the use of liposomal irinotecan (MM-398) with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV). Each derivative explores a specific axis of innovation to anticipate and render future incremental improvements obvious or non-novel to a Person Having Ordinary Skill in the Art (POSITA).

Core Claims Addressed

The primary claims targeted for this defensive disclosure are:

• Claim 1: A method of treating metastatic adenocarcinoma of the pancreas in a human patient who has not previously received an antineoplastic agent to treat the metastatic adenocarcinoma of the pancreas, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of: (a) 60 mg/m² of liposomal irinotecan; (b) 60 mg/m² oxaliplatin; (c) 200 mg/m² of the (l)-form of leucovorin or 400 mg/m² of the (l+d) racemic form of leucovorin; and (d) 2,400 mg/m² 5-fluorouracil; to treat the metastatic adenocarcinoma of the pancreas in the human patient.
• Claim 12: A method of treating metastatic adenocarcinoma of the pancreas in a human patient who has not previously received gemcitabine to treat the metastatic adenocarcinoma of the pancreas, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of: (a) 60 mg/m² of liposomal irinotecan; (b) 60 mg/m² oxaliplatin; (c) 200 mg/m² of the (l)-form of leucovorin or 400 mg/m² of the (l+d) racemic form of leucovorin; and (d) 2,400 mg/m² 5-fluorouracil; to treat the metastatic adenocarcinoma of the pancreas in the human patient.

Given that Claim 12 is a specific instance of Claim 1, the derivatives below are broadly applicable to both.

---

Derivative Variations

1. Material & Component Substitution

Derivative 1.1: Alternative Liposome Lipid Composition

• Enabling Description: The liposomal irinotecan (MM-398) described in US11344552B2 primarily uses 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and N-(carbonylmethoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (MPEG-2000-DSPE). This derivative proposes substituting DSPC with hydrogenated soy phosphatidylcholine (HSPC) or dimyristoylphosphatidylcholine (DMPC), and/or replacing cholesterol with ergosterol or phytosterols to alter membrane fluidity and stability. Furthermore, the PEGylated lipid MPEG-2000-DSPE could be replaced with PEG-containing block copolymers like polyethylene glycol-poly(lactic-co-glycolic acid) (PEG-PLGA) for enhanced stealth properties or alternative targeting ligands. The irinotecan payload, while still encapsulated as a sucrosofate salt, could be substituted with an irinotecan succinate or lactate salt to modify drug loading and release kinetics from the liposomal core. The preparation methods would involve established thin-film hydration followed by extrusion or microfluidic mixing techniques.

classDiagram
    class Liposome {
        - LipidBilayer: (HSPC | DMPC) + (Cholesterol | Ergosterol | Phytosterol)
        - PEGylationAgent: (MPEG-2000-DSPE | PEG-PLGA)
        - EncapsulatedPayload: Irinotecan (Sucrosofate | Succinate | Lactate)
    }
    class Irinotecan {
        + SucrosofateSalt
        + SuccinateSalt
        + LactateSalt
    }
    class LipidComponent {
        + DSPC
        + HSPC
        + DMPC
        + Cholesterol
        + Ergosterol
        + Phytosterol
    }
    class PEGylationComponent {
        + MPEG-2000-DSPE
        + PEG-PLGA
    }
    Liposome "1" -- "1" EncapsulatedPayload
    Liposome "1" -- "2" LipidComponent
    Liposome "1" -- "1" PEGylationComponent

Derivative 1.2: Alternative Platinum-Based Agent

• Enabling Description: The patent specifies oxaliplatin as the platinum-based antineoplastic agent. This derivative substitutes oxaliplatin with carboplatin or cisplatin, which are also widely used platinum coordination complexes with DNA cross-linking mechanisms. The equivalent therapeutic doses would be determined based on their respective dose-limiting toxicities and efficacy profiles in pancreatic cancer, maintaining the bi-weekly administration schedule. For instance, carboplatin could be administered at an AUC (Area Under the Curve) target of 5-6 mg·min/mL, co-administered with the liposomal irinotecan, 5-FU, and leucovorin. This requires adjustments in infusion duration and potential co-medications for toxicity management (e.g., anti-emetics for cisplatin).

flowchart TD
    A[Patient with mPAC] --> B{Antineoplastic Therapy};
    B --> C1(Liposomal Irinotecan);
    B --> C2(Platinum Agent);
    B --> C3(Leucovorin);
    B --> C4(5-Fluorouracil);
    C2 -- Substitution --> C2a(Oxaliplatin);
    C2 -- Alternative 1 --> C2b(Carboplatin AUC 5-6);
    C2 -- Alternative 2 --> C2c(Cisplatin 75-100 mg/m^2);
    C1 & C2a & C3 & C4 --> D[Bi-weekly regimen];
    C1 & C2b & C3 & C4 --> D;
    C1 & C2c & C3 & C4 --> D;

Derivative 1.3: Alternative Pyrimidine Antagonist and Folate Analog

• Enabling Description: Instead of 5-fluorouracil, this derivative uses capecitabine, an orally administered prodrug of 5-FU, at an equivalent systemic exposure dose (e.g., 1000-1250 mg/m² orally twice daily for 14 days, followed by 7 days rest, synchronized with the bi-weekly liposomal irinotecan/oxaliplatin schedule). For leucovorin, a more potent reduced folate like raltitrexed could be considered as a substitute, or its levo-isomer, levoleucovorin, could be administered at half the racemic dose (e.g., 100 mg/m²). The oral administration of capecitabine would modify the overall regimen delivery, potentially reducing the need for continuous IV infusion days, thereby improving patient convenience while maintaining the synergistic mechanism of pyrimidine antagonism.

graph TD
    A[Antineoplastic Therapy] --> B[Liposomal Irinotecan];
    A --> C[Platinum Agent];
    A --> D{Pyrimidine Antagonist};
    A --> E{Folate Analog};
    D -- (Substitute 5-FU) --> D1[Capecitabine (oral)];
    E -- (Substitute Leucovorin) --> E1[Levoleucovorin];
    E -- (Alternative Potent) --> E2[Raltitrexed];
    D1 & E1/E2 --> F[Bi-weekly schedule coordination];

2. Operational Parameter Expansion

Derivative 2.1: Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) Delivery of Liposomal Irinotecan

• Enabling Description: For patients with predominant peritoneal carcinomatosis from metastatic pancreatic cancer, the liposomal irinotecan component of the combination therapy is delivered via Hyperthermic Intraperitoneal Chemoperfusion (HIPEC). After maximal cytoreductive surgery, a heated (41-43°C) perfusate containing liposomal irinotecan (e.g., at a concentration of 150-200 mg/L) is circulated throughout the peritoneal cavity for 60-90 minutes. The oxaliplatin, 5-FU, and leucovorin are administered intravenously pre-operatively or in a staggered IV fashion post-HIPEC. This approach delivers a high local concentration of the liposomal agent to peritoneal metastases, potentially overcoming permeability barriers and enhancing drug uptake due to hyperthermia, while minimizing systemic exposure of the liposomal component during the HIPEC phase.

sequenceDiagram
    participant Patient
    participant Surgeon
    participant Oncologist
    participant PerfusionSystem
    Surgeon->>Patient: Cytoreductive Surgery
    Oncologist->>Patient: IV Oxaliplatin, 5-FU, LV (Pre-op)
    Surgeon->>PerfusionSystem: Connect Peritoneal Catheters
    PerfusionSystem->>Patient: Infuse Heated Liposomal Irinotecan Perfusate (HIPEC)
    PerfusionSystem-->>Patient: Recirculate for 60-90 min
    PerfusionSystem->>Patient: Drain Perfusate
    Oncologist->>Patient: Resume IV Combination Therapy (Post-op)

Derivative 2.2: Continuous Infusion of Liposomal Irinotecan and Oxaliplatin via Implantable Pump

• Enabling Description: The bi-weekly bolus/short infusion administration of liposomal irinotecan and oxaliplatin is replaced by a continuous, low-dose infusion utilizing a fully implantable subcutaneous pump and an indwelling central venous catheter. The liposomal irinotecan (e.g., 15-20 mg/m²/week) and oxaliplatin (e.g., 20-30 mg/m²/week) are compounded into a compatible formulation or delivered via separate channels from a multi-channel pump. 5-FU and leucovorin are still administered bi-weekly via standard IV infusion or as oral equivalents. This minimizes peak drug concentrations, potentially reducing acute toxicities, and provides sustained tumor exposure, leveraging the prolonged SN-38 release profile of liposomal irinotecan. The pump requires programming for individualized dosing and remote monitoring capabilities.

flowchart LR
    A[Implantable Pump] --> B[Central Venous Catheter];
    B --> C[Patient Venous System];
    C -- Sustained Exposure --> D[Metastatic Pancreatic Tumor];
    subgraph Pump Contents
        P1(Liposomal Irinotecan)
        P2(Oxaliplatin)
    end
    A -- Delivers --> P1;
    A -- Delivers --> P2;
    E[5-FU/Leucovorin] -- Bi-weekly IV or oral --> C;

Derivative 2.3: Microfluidic Synthesis of Liposomal Irinotecan with High-Frequency Sonication

• Enabling Description: The manufacturing process for liposomal irinotecan is scaled from traditional bulk methods to continuous-flow microfluidic synthesis coupled with high-frequency (e.g., 2-5 MHz) sonication. This allows for precise control over lipid hydration, self-assembly, and drug encapsulation, yielding highly uniform liposome sizes (e.g., 50-70 nm diameter) and lamellarity, potentially improving batch-to-batch consistency and in vivo pharmacokinetics. The high-frequency sonication, applied during the hydration or extrusion step, promotes rapid and controlled vesicle formation with improved drug loading efficiency compared to conventional methods. The resulting liposomes are then sterile-filtered and formulated for intravenous administration in the described combination therapy.

graph TD
    A[Lipid & Irinotecan Precursors] --> B{Microfluidic Mixer};
    B --> C{High-Frequency Sonication Module};
    C --> D[Liposome Extrusion/Sizing];
    D --> E[Purification & Concentration];
    E --> F[Quality Control (Size, PDI, Drug Load)];
    F --> G[Sterile Filtration];
    G --> H[Final Drug Product (Liposomal Irinotecan)];
    subgraph Process Parameters
        Temp(Temperature Control)
        Pressure(Pressure Control)
        Flow(Flow Rate Control)
        Freq(Sonication Frequency)
    end
    B -- Controls --> Temp;
    B -- Controls --> Pressure;
    B -- Controls --> Flow;
    C -- Controls --> Freq;

3. Cross-Domain Application

Derivative 3.1: Targeted Agricultural Pest Control

• Enabling Description: The principle of targeted, sustained release of multiple active agents via liposomal encapsulation, combined with dose-responsive adaptation, is applied to agricultural pest control. A "liposomal bio-pesticide" is formulated, encapsulating synergistic combinations of insecticides (e.g., pyrethroids, neonicotinoids) and/or entomopathogenic fungi spores. These liposomes are designed for targeted delivery to specific insect pests on crops, either via foliar spray or soil drench. The liposomal formulation protects the active ingredients from UV degradation and environmental washout, providing prolonged efficacy. Dosing is adjusted based on real-time pest load monitoring (e.g., IoT insect traps) and crop health, similar to how human patient toxicity guides chemotherapy adjustments.

flowchart TD
    A[Crop Field] --> B{Pest Monitoring (IoT Traps)};
    B -- Real-time Data --> C[Pest Load Analysis];
    C -- Optimal Regimen --> D[Automated Sprayer/Drencher];
    D --> E[Liposomal Bio-pesticide];
    E -- Targeted Delivery --> A;
    subgraph Liposomal Bio-pesticide
        L1(Liposome Carrier)
        L2(Insecticide 1)
        L3(Insecticide 2 / Bio-agent)
    end
    E -- Contains --> L1;
    L1 -- Encapsulates --> L2;
    L1 -- Encapsulates --> L3;

Derivative 3.2: Precision Industrial Corrosion Inhibition

• Enabling Description: In complex industrial piping systems or structural components susceptible to localized corrosion, a "liposomal anti-corrosion agent" system is deployed. Liposomes encapsulate a combination of synergistic corrosion inhibitors (e.g., benzotriazole for copper, organic phosphonates for steel) and pH-buffering agents. These liposomes are introduced into the fluid circulating through the system or applied topically to susceptible areas. The liposomal structure allows for slow, sustained release of inhibitors, particularly at sites of incipient corrosion where pH changes or enzymatic activity might trigger localized liposome degradation and payload release. Dosing of the liposomal agent is adjusted based on continuous electrochemical impedance spectroscopy (EIS) or ultrasonic thickness measurements from IoT sensors indicating corrosion progression.

graph LR
    A[Industrial System (Pipes/Structures)] -- Susceptible To --> C(Corrosion);
    B[Liposomal Anti-Corrosion Agent] --> A;
    subgraph Liposomal Agent
        LA1(Liposome Shell)
        LA2(Corrosion Inhibitor A)
        LA3(Corrosion Inhibitor B)
        LA4(pH Buffer)
    end
    B -- Contains --> LA1;
    LA1 -- Encapsulates --> LA2;
    LA1 -- Encapsulates --> LA3;
    LA1 -- Encapsulates --> LA4;
    D[IoT Corrosion Sensors (EIS, UT)] --> E[Monitoring & Analysis Unit];
    E -- Adaptive Dosing --> B;

Derivative 3.3: Autonomous Micro-Robot for Electronics Repair

• Enabling Description: The concept of localized, multi-agent delivery and adaptive dosing is applied to autonomous micro-robots for precision repair of printed circuit boards (PCBs) or micro-electromechanical systems (MEMS). These micro-robots are equipped with on-board reservoirs for "liposomal nano-solder" (nanoparticles of solder encapsulated in temperature-sensitive liposomes) and "liposomal etching agents" (encapsulated mild acids or bases for targeted material removal). Guided by AI-driven visual inspection and fault detection, the micro-robot navigates to specific defect sites. It applies the liposomal agents, triggering release via localized thermal energy or specific chemical cues from the damaged area. The multi-agent approach allows for precise deposition or removal of material. The repair process is iterative, with dosing adjusted based on real-time optical or electrical feedback, mimicking chemotherapy dose modifications based on patient response.

stateDiagram-v2
    state "Micro-Robot Status" as MicroRobot
    MicroRobot --> Idle
    Idle --> DetectFault: (AI Vision)
    DetectFault --> NavigateToFault: (Actuation)
    NavigateToFault --> ApplyLiposomalAgents: (Precision Dispensing)
    ApplyLiposomalAgents --> TriggerRelease: (Thermal/Chemical Cue)
    TriggerRelease --> AssessRepair: (Optical/Electrical Feedback)
    AssessRepair --> ApplyLiposomalAgents: (Repair Incomplete)
    AssessRepair --> CompleteRepair: (Repair Complete)
    CompleteRepair --> Idle

4. Integration with Emerging Tech

Derivative 4.1: AI-Driven Personalized Dosing and Schedule Optimization

• Enabling Description: The core combination therapy is administered under the guidance of an AI system that continuously optimizes personalized dosing and scheduling. Real-time patient data from wearable IoT sensors (e.g., continuous glucose monitoring, activity trackers, heart rate variability, sleep patterns) and electronic health records (EHR) including pharmacogenomic data (e.g., UGT1A1*28 allele status for irinotecan metabolism) are fed into a machine learning model. This AI model predicts patient-specific toxicity risk and treatment response to dynamically adjust the dosages of liposomal irinotecan, oxaliplatin, 5-FU, and leucovorin, as well as their administration intervals, within predefined safe ranges. The goal is to maximize therapeutic efficacy while minimizing adverse events, adapting beyond the fixed bi-weekly schedule and standard dose reductions.

flowchart TD
    A[Patient Data Stream] --> B{IoT Sensors};
    A --> C{EHR/Pharmacogenomics};
    B & C --> D[Data Integration Layer];
    D --> E(AI Dosing Optimization Engine);
    E -- Predicted Toxicity/Efficacy --> F{Personalized Treatment Plan};
    F --> G[Automated Infusion System];
    G -- Administers --> H(Combination Therapy);
    H --> A;

Derivative 4.2: IoT-Enabled Real-time Toxicity Monitoring and Early Intervention

• Enabling Description: Patients undergoing the combination therapy are equipped with a suite of IoT-connected medical sensors for continuous, real-time monitoring of key physiological parameters indicative of chemotherapy-induced toxicities. This includes continuous non-invasive blood count monitoring (e.g., via microfluidic patches for leukocyte/neutrophil trends), smart wearables for temperature and activity, and biosensors for early detection of gastrointestinal distress markers in stool samples. Data is securely transmitted to a cloud platform, where algorithms detect deviations from baseline or predictive thresholds for Grade 3/4 hematotoxicity, diarrhea, or neuropathy. Automated alerts notify clinicians, enabling proactive dose adjustments or supportive care interventions before severe adverse events manifest, improving patient safety and treatment adherence.

graph TD
    A[Patient] --> B{IoT Medical Sensors};
    B --> C(Local Data Gateway);
    C -- Secure Transmission --> D[Cloud Data Platform];
    D --> E(Real-time Analytics Engine);
    E -- Anomaly Detection --> F{Clinician Dashboard/Alerts};
    F -- Intervention Recommendation --> G[Treatment Adjustment / Support];
    G --> A;
    subgraph Sensors
        S1(Non-invasive Blood Count)
        S2(Temperature/Activity)
        S3(GI Biomarkers)
    end
    B -- Collects --> S1;
    B -- Collects --> S2;
    B -- Collects --> S3;

Derivative 4.3: Blockchain for Secure Clinical Trial Data and Supply Chain Verification

• Enabling Description: Clinical trials evaluating new formulations or schedules of the liposomal irinotecan combination therapy, as well as the commercial supply chain for the drugs, leverage blockchain technology. Patient enrollment, consent, treatment administration logs, adverse event reporting, and outcome data from all participating sites are recorded as immutable transactions on a permissioned blockchain. This ensures data integrity, transparency, and auditability for regulatory submissions and research reproducibility. For the supply chain, each batch of liposomal irinotecan, oxaliplatin, 5-FU, and leucovorin is tracked from manufacturing through distribution to patient administration using unique cryptographic identifiers. This verifies drug authenticity, monitors storage conditions (e.g., temperature excursions via IoT sensors linked to blockchain), and prevents counterfeiting, ensuring the quality and safety of the combination therapy.

sequenceDiagram
    participant Manufacturer
    participant Distributor
    participant Pharmacy
    participant Patient
    participant Clinician
    participant AI_System
    participant Blockchain
    Manufacturer->>Blockchain: Register Drug Batch (Hash)
    Distributor->>Blockchain: Receive & Verify Batch (Hash)
    Pharmacy->>Blockchain: Dispense & Verify Batch (Hash)
    Clinician->>Blockchain: Record Treatment Event (Patient ID, Dose, Date, AE)
    Patient->>Blockchain: Submit Consent / Outcome Data
    AI_System->>Blockchain: Access Anonymized Trial Data
    Blockchain-->>Manufacturer: Supply Chain Audit
    Blockchain-->>Clinician: Data Integrity Verification

5. The "Inverse" or Failure Mode

Derivative 5.1: Bio-degradable, Self-Deactivating Liposomal Irinotecan for Safe Failure

• Enabling Description: A modified liposomal irinotecan formulation is developed with a built-in "fail-safe" mechanism. The liposome membrane is engineered with specific enzymatic cleavage sites or pH-sensitive lipids that, upon exposure to abnormally high concentrations of specific endogenous metabolites (e.g., elevated lactate or specific proteases indicative of severe systemic toxicity or organ dysfunction), rapidly degrade the liposome and release irinotecan. Simultaneously, the encapsulated irinotecan is co-formulated with a bio-reversible antagonist or an enzyme that rapidly metabolizes irinotecan/SN-38, essentially "self-deactivating" the cytotoxic agent systemically if severe toxicity occurs. This provides a safety shut-off valve, reducing the active drug burden in critical situations and shifting the system into a limited-functionality, detoxification mode.

stateDiagram
    [*] --> HealthyState
    HealthyState --> AdministerTherapy
    AdministerTherapy --> MonitorToxicity
    MonitorToxicity --> SevereToxicityDetected: (Elevated Biomarkers)
    SevereToxicityDetected --> TriggerLiposomeDegradation
    TriggerLiposomeDegradation --> DrugRelease
    DrugRelease --> DrugDeactivation: (Co-encapsulated Antagonist/Enzyme)
    DrugDeactivation --> SafeFailureMode
    SafeFailureMode --> Recovery / DiscontinueTreatment
    MonitorToxicity --> StableState: (No Severe Toxicity)
    StableState --> AdministerTherapy

Derivative 5.2: Low-Power, Dose-Skipping Regimen for Managing Chronic Toxicity

• Enabling Description: In patients developing chronic, non-resolving Grade 2 toxicities (e.g., persistent neuropathy from oxaliplatin, cumulative myelosuppression) after multiple cycles of the full combination therapy, the regimen transitions to a "low-power" mode. This involves a planned, sequential discontinuation or significant dose reduction (e.g., >50%) of the most offending agent (e.g., oxaliplatin first, then 5-FU/LV) while maintaining liposomal irinotecan monotherapy or a liposomal irinotecan/5-FU doublet at a reduced frequency (e.g., every 3-4 weeks instead of bi-weekly). The goal is to maintain some anti-tumor activity with a significantly improved quality of life and reduced cumulative toxicity, essentially operating in a "limited-functionality" mode that prioritizes patient well-being over maximal, but unsustainable, tumor control.

flowchart TD
    A[Full Combination Therapy (Bi-weekly)] --> B{Assess Chronic Toxicity};
    B -- Grade 2+ Persistent --> C[Transition to Low-Power Mode];
    C --> D1(Discontinue Oxaliplatin);
    C --> D2(Reduce 5-FU/LV Dose/Frequency);
    C --> D3(Maintain Liposomal Irinotecan Monotherapy);
    D3 -- OR --> D4(Liposomal Irinotecan + Reduced 5-FU/LV);
    D1 & D2 & D3/D4 --> E[Reduced Frequency (e.g., Q3-4W)];
    E --> F[Improved QoL / Reduced Cumulative Toxicity];

Derivative 5.3: Liposomal Irinotecan with Encapsulated "Neutralizer" for Controlled Deactivation

• Enabling Description: The liposomal irinotecan is co-encapsulated with a metabolically inert "neutralizer" compound (e.g., a specific non-toxic peptide or small molecule) that, upon controlled external activation (e.g., by a low-frequency ultrasonic pulse or a specific near-infrared light exposure), is released along with irinotecan. The neutralizer then binds to and sequesters circulating free SN-38 (the active metabolite of irinotecan) in the bloodstream, forming an inactive complex that is rapidly cleared. This allows for clinician-controlled deactivation or attenuation of irinotecan's systemic activity if acute, unexpected toxicity arises, offering a "remote shut-off" for the cytotoxic component of the combination therapy.

sequenceDiagram
    participant Clinician
    participant Patient
    participant Liposome
    participant Bloodstream
    participant Neutralizer
    Clinician->>Patient: Administer Liposomal Irinotecan (co-encapsulated with Neutralizer)
    Liposome->>Bloodstream: Slow Release of Irinotecan/SN-38
    Clinician->>Clinician: Detect Acute Toxicity
    Clinician->>Patient: Apply External Activation (e.g., Ultrasound)
    Liposome->>Bloodstream: Rapid Release of Neutralizer
    Neutralizer->>Bloodstream: Bind to free SN-38
    Bloodstream->>Bloodstream: Form Inactive Complex
    Bloodstream->>Patient: Rapid Clearance of Inactive Complex
    Patient->>Patient: Reduced Systemic Toxicity

---

Combination Prior Art Scenarios with Open-Source Standards

Here are three scenarios combining the core technology of US Patent 11,344,552 with existing open-source standards to demonstrate obviousness or non-novelty of such integrations:

Scenario 1: Integration with FHIR (Fast Healthcare Interoperability Resources) for Standardized Patient Data Exchange

• Description: The administration of combination therapy involving liposomal irinotecan, oxaliplatin, 5-FU, and leucovorin for metastatic pancreatic adenocarcinoma, including dose adjustments based on toxicity, is well-documented. A POSITA would find it obvious to integrate this treatment protocol with an open-source health information exchange standard like FHIR (Fast Healthcare Interoperability Resources). This involves mapping patient demographic data, diagnosis codes (e.g., ICD-10 for metastatic pancreatic adenocarcinoma), drug prescriptions, administration records, adverse event reports (using CTCAE v4.0 or later), and laboratory results (e.g., ANC, WBC, platelet counts, bilirubin, creatinine) to FHIR resources (e.g., Patient, Condition, MedicationRequest, MedicationAdministration, Observation, AdverseEvent). This integration would enable standardized, secure, and efficient exchange of clinical data between different electronic health record (EHR) systems, research databases, and specialized oncology platforms, facilitating better patient management and real-world evidence generation for this specific therapy. This is a common practice for any novel treatment regimen to ensure interoperability and data utility.

Scenario 2: Utilizing OpenMRS for Clinical Protocol Management and Decision Support

• Description: Given the detailed dosing schedules, toxicity management guidelines (e.g., dose reductions for hematotoxicity or UGT1A1*28 allele carriers), and monitoring requirements outlined for the liposomal irinotecan combination therapy, it would be obvious for a POSITA to implement these protocols within an open-source electronic medical record system designed for clinical management and decision support, such as OpenMRS. This would involve configuring OpenMRS forms for recording treatment cycles, drug dosages (e.g., 60 mg/m² liposomal irinotecan, 60 mg/m² oxaliplatin), infusion times, pre-medications (e.g., dexamethasone, 5-HT3 antagonist), and laboratory parameters (ANC, WBC, platelet count, bilirubin, diarrhea grade). The system could incorporate rule-based alerts for dose holding criteria (e.g., ANC <1500/mm³) and automated suggestions for dose reductions based on observed toxicities, directly applying the patent's clinical management aspects within an widely accessible open-source framework.

Scenario 3: Employing Open-Source Bioinformatics Tools for Pharmacogenomic-Guided Dosing

• Description: The patent explicitly mentions considering UGT1A1*28 allele status for evaluating dose-limiting toxicities and adjusting irinotecan doses. A POSITA would find it obvious to leverage open-source bioinformatics tools and databases (e.g., publicly available pipelines on platforms like Galaxy, or databases like PharmGKB for pharmacogenomic information) to inform personalized dosing for the liposomal irinotecan component of the therapy. This would involve processing patient genetic data (e.g., SNP array or sequencing data for UGT1A1*28 genotyping) using open-source algorithms to predict irinotecan metabolism. The output from these tools (e.g., identification of homozygous UGT1A1*28 allele status) would then directly trigger recommended dose adjustments for liposomal irinotecan (e.g., a 25% reduction from 60 mg/m²), integrating the pharmacogenomic aspect mentioned in the patent with established open-source computational biology practices.